- Home
- BZUN vs IPHA Comparison
BZUN vs IPHA Comparison
Compare BZUN & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BZUN
- IPHA
- Stock Information
- Founded
- BZUN 2007
- IPHA 1999
- Country
- BZUN China
- IPHA France
- Employees
- BZUN N/A
- IPHA 179
- Industry
- BZUN Catalog/Specialty Distribution
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- BZUN Consumer Discretionary
- IPHA Health Care
- Exchange
- BZUN Nasdaq
- IPHA Nasdaq
- Market Cap
- BZUN 166.3M
- IPHA 192.7M
- IPO Year
- BZUN N/A
- IPHA 2019
- Fundamental
- Price
- BZUN $2.35
- IPHA $2.33
- Analyst Decision
- BZUN Buy
- IPHA Strong Buy
- Analyst Count
- BZUN 2
- IPHA 1
- Target Price
- BZUN $2.20
- IPHA $11.50
- AVG Volume (30 Days)
- BZUN 237.7K
- IPHA 5.8K
- Earning Date
- BZUN 08-28-2024
- IPHA 09-12-2024
- Dividend Yield
- BZUN N/A
- IPHA N/A
- EPS Growth
- BZUN N/A
- IPHA N/A
- EPS
- BZUN N/A
- IPHA N/A
- Revenue
- BZUN $1,235,027,314.00
- IPHA $68,134,188.00
- Revenue This Year
- BZUN $5.22
- IPHA N/A
- Revenue Next Year
- BZUN $5.32
- IPHA $105.84
- P/E Ratio
- BZUN N/A
- IPHA N/A
- Revenue Growth
- BZUN 5.56
- IPHA 6.88
- 52 Week Low
- BZUN $1.90
- IPHA $1.81
- 52 Week High
- BZUN $3.61
- IPHA $3.15
- Technical
- Relative Strength Index (RSI)
- BZUN 52.83
- IPHA 54.07
- Support Level
- BZUN $2.23
- IPHA $2.22
- Resistance Level
- BZUN $2.35
- IPHA $2.41
- Average True Range (ATR)
- BZUN 0.11
- IPHA 0.14
- MACD
- BZUN 0.01
- IPHA 0.00
- Stochastic Oscillator
- BZUN 85.19
- IPHA 67.65
About BZUN Baozun Inc.
Baozun Inc is an e-commerce service partner that helps brands execute their e-commerce strategies in China by selling their goods directly to customers online or by providing services to assist with their e-commerce operations. Its integrated end-to-end e-commerce service capabilities, omni-channel expertise, and technology-driven solutions. Company have two operating segments namely E-Commerce (including BEC and BZI) and Brand Management (BBM).
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.